<DOC>
	<DOCNO>NCT00314275</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics ( PK ) safety associate ABT-578 administer use Medtronic Endeavor Drug Eluting Coronary Stent system treatment single de novo lesion native coronary artery 2.5 - 3.5 mm diameter .</brief_summary>
	<brief_title>The ENDEAVOR Pharmacokinetic ( PK ) Registry : The Medtronic Endeavor Drug Eluting Coronary Stent System</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>The patient least 18 year age . The patient clinical evidence ischemic heart disease , stable unstable angina , silent ischemia , positive functional study . The patient acceptable candidate percutaneous transluminal coronary angioplasty ( PTCA ) , stenting , emergent coronary artery bypass graft ( CABG ) surgery . Female patient childbearing potential must negative pregnancy test within 7 day procedure . The patient patient 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board respective clinical site . A known hypersensitivity contraindication aspirin , heparin bivalirudin , ticlopidine clopidogrel , cobalt , nickel , chromium , molybdenum , polymer coating , sensitivity contrast medium , adequately premedicated . History allergic reaction significant sensitivity drug similar ABT578 , rapamycin , tacrolimus , everolimus , analog derivative . A platelet count &lt; 100,000 cells/mm³ &gt; 700,000 cells/mm³ , white blood cell ( WBC ) count &lt; 3,000 cells/mm³ . A creatinine level &gt; 2.0 mg/dL within seven day prior index procedure . Evidence acute myocardial infarction within 72 hour intend treatment ( define : Q wave nonQ wave myocardial infarction creatine kinase [ CK ] enzymes great equal 2 X upper laboratory normal presence creatine kinase myocardialband isoenzyme [ CKMB ] elevate institution 's upper limit normal ) . Previous percutaneous coronary intervention ( PCI ) target vessel within 9 month preprocedure . Planned PCI vessel within 30 day postprocedure . During index procedure , target lesion require treatment device PTCA prior stent placement ( , limit : cut balloon , directional coronary atherectomy , excimer laser , rotational atherectomy , thrombectomy , etc. ) . History stroke transient ischemic attack within prior 6 month . Active peptic ulcer upper gastrointestinal ( GI ) bleeding within prior 6 month . History bleed diathesis coagulopathy refuse blood transfusion . Concurrent medical condition life expectancy le 12 month . Any previous plan treatment target vessel antirestenotic therapy include , limited , brachytherapy . Currently participate investigational drug another device study complete primary endpoint clinically interfere current study endpoint ; require coronary angiography , intravascular ultrasound ( IVUS ) coronary artery imaging procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>PCI</keyword>
	<keyword>Drug Eluting Stent</keyword>
</DOC>